The combination therapy for cystic fibrosis – tezacaftor with ivacaftor (Symdeko) – is to be PBS reimbursed for patients 12 years and older who are homozygous for the F508del mutation in the CFTR gene. Symdeko will also be made available for people with CF who have one copy of the F508del mutation and another responsive residual function (RF) ...
Symdeko and Orkambi get PBS subsidies for CF patients
By Michael Woodhead
22 Oct 2019